We advise that only clinically validated HPV assays which have fulfilled internationally
accepted performance criteria be used for primary cervical screening. Further, assays …

Establishing human papillomavirus (HPV) as the necessary cause of cervical cancer has
paved the way for disease management strategies that focus on the virus through primary …

BACKGROUND:: Cervical screening by cytology is effective but lacks sensitivity. The
addition of human papillomavirus (HPV) testing can improve the effectiveness of screening …

Background Although cervical screening using Human Papillomavirus (HPV) testing is
globally recommended public health policy, there has been no international proficiency …

Background Testing for high-risk HPV is more effective in primary cervical cancer screening
than the cytological examination of a Pap smear. Separate genotyping may be useful for …

The human papillomavirus is one of the most common sexually transmitted viruses, and an
infection from this virus may become persistent, leading to diseases such as cervical cancer …

Testing for high-risk types of alpha human papillomaviruses (HPV) is an invaluable part of
clinical guidelines for cervical carcinoma screening, management and treatment. In this …

The management and prevention of cervical cancer should change definitively with DNA
testing for high-risk HPV, which is more sensitive than cytology whether used for triage …

ABSTRACT The Validation of Human Papillomavirus (HPV) Genotyping Tests (VALGENT)
studies offer an opportunity to clinically validate HPV assays for use in primary screening for …

ABSTRACT The Aptima HPV assay (Hologic Gen-Probe, San Diego, CA) is an FDA-
approved assay for detecting human papillomavirus (HPV) E6/E7 mRNA from 14 high-risk …